Shanghai Pharma Reports Profit, Plans Dividend

Shanghai Pharmaceuticals Holding Co (HK:2607) has released an update.

Shanghai Pharmaceuticals Holding Co., Ltd. has announced its unaudited interim financial results for the first half of 2024, revealing a consolidated net profit of RMB 2.94 billion. The company plans to reward shareholders with a cash dividend of RMB 0.80 per ten shares, which amounts to 10.07% of its net profit. The interim report, yet to be audited, confirms that there are no significant risks affecting the company’s operations during the reporting period.

For further insights into HK:2607 stock, check out TipRanks’ Stock Analysis page.